Gilead Sciences

GILD

Market cap $174B

In the most recent trading session, Gilead Sciences (GILD) closed at $140.45, indicating a +1.02% shift from the previous trading day.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #EndHIV--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. Bringing together th.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

SAN FRANCISCO--(BUSINESS WIRE)-- #AHFcares--Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing.

Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #AHFcares--AHF Slams Gilead for Role in Florida AIDS Drug Crisis.

Gilead's $5B Tubulis deal expands its ADC pipeline, boosting oncology ambitions as the company accelerates strategic acquisitions beyond HIV.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead's oncology pipeline. To date, Gilead has leveraged Tempus' extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that Gilead Sciences, Inc. has exercised the first of its options to exclusively license a novel oncology target discovered and validated through Cartography's proprietary ATLAS and SUMMIT platforms arising out of the parties' collaboration. The option exercise represents a key milestone in the.

Gilead Sciences (GILD) reached $141.54 at the closing of the latest trading day, reflecting a +1.97% change compared to its last close.